Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:48:47 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Q:TARA - PROTARA THERAPEUTICS INC - https://protaratx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TARA - Q6.02.62·2.850.12.75+0.020.7241.55627872.76  2.89  2.665.24  1.0416:00:00Apr 0515 min RT 2¢

Recent Trades - Last 10 of 787
Time ETExPriceChangeVolume
16:00:00Q2.750.02260
16:00:00Q2.750.02100
16:00:00Q2.750.021,732
16:00:00Q2.750.029
16:00:00Q2.750.0288
16:00:00Q2.750.02801
16:00:00Q2.750.02100
16:00:00Q2.750.0291
16:00:00Q2.750.0210
16:00:00Q2.750.021

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-05 08:04U:TARANews ReleaseProtara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
2024-04-05 08:02U:TARANews ReleaseProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
2024-04-05 08:00U:TARANews ReleaseProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
2024-03-13 08:00U:TARANews ReleaseProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-28 08:00U:TARANews ReleaseProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
2024-01-31 07:30U:TARANews ReleaseProtara Therapeutics to Participate in Upcoming Investor Conferences
2023-11-30 08:30U:TARANews ReleaseProtara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
2023-11-03 08:00U:TARANews ReleaseProtara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
2023-10-23 08:00U:TARANews ReleaseProtara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
2023-09-20 08:30U:TARANews ReleaseProtara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
2023-09-05 07:30U:TARANews ReleaseProtara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-03 08:00U:TARANews ReleaseProtara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
2023-05-15 08:00U:TARANews ReleaseProtara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
2023-05-04 08:00U:TARANews ReleaseProtara Therapeutics Announces First Quarter 2023 Financial Results and Business Update
2023-05-02 08:00U:TARANews ReleaseProtara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
2023-04-28 08:00U:TARANews ReleaseProtara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development